Traversa, Sanofi-aventis To Jointly Develop RNAi Delivery Technology
As per the agreement, the companies are expected to study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology. Hans
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.